Form 4: Pfizer EVP Lidia Fonseca Exercises Stock Rights

Pfizer Executive Vice President Lidia Fonseca reported the exercise of stock appreciation rights and subsequent share disposals for tax and exercise price coverage.

Summary

• Lidia Fonseca, Executive Vice President of Pfizer Inc., reported transactions involving Pfizer common stock.
• On February 25, 2026, Fonseca acquired 56,888 shares of common stock at an exercise price of $33.82 per share through the earn-out of stock appreciation rights (SARs), including dividend equivalents.
• Concurrently, 1,058 shares were disposed of at $27.09 per share to satisfy tax obligations related to the SAR earn-out.
• An additional 54,066 shares were disposed of at $26.92 per share to cover the payment of the exercise price for the SARs.
• Following these transactions, Fonseca beneficially owns 46,455 shares of Pfizer common stock directly.
• The price for covering the exercise price was based on the 20-day average of closing prices ending on the settlement date.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event, reflecting the successful vesting and exercise of executive compensation, which is a normal course of business and indicates the executive is realizing value from their equity awards.

Positives

• Executive Lidia Fonseca realized value from her stock appreciation rights, indicating a successful compensation event.
• The exercise price of the SARs was $33.82, suggesting the stock price was at or above this level for the SARs to be in-the-money.

Negatives

• A significant portion of the acquired shares (54,066 shares) was immediately disposed of to cover the exercise price, and another 1,058 shares for tax obligations, reducing the net shares retained.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that this Form 4 filing represents a routine insider transaction related to executive compensation, specifically the exercise of stock appreciation rights. Such transactions are common for executives and are generally not indicative of significant shifts in company strategy or performance, but rather the realization of previously granted equity compensation.

Stakeholder Impact

• Shareholders: The transaction is a routine compensation event and does not directly impact the company's operational performance or strategic direction. It reflects an executive realizing value from their equity awards.
• Employees: No direct impact on employees is indicated by this filing.
• Customers, Suppliers, Creditors: No direct impact on these stakeholders is indicated by this filing.

Key Dates

Recommendation

This Form 4 details a routine insider transaction involving the exercise of stock appreciation rights and subsequent share disposals for tax and exercise price coverage. It is a standard compensation event for an executive and does not provide new information that would fundamentally alter the investment thesis for Pfizer. Therefore, a 'hold' recommendation is appropriate as it does not signal a change in the company's underlying value or prospects.

Keywords

Pfizer, PFE, Lidia Fonseca, Form 4, Insider Transaction, Stock Appreciation Rights, Executive Compensation, Share Ownership